文献速递帕金森病与运动障碍神经肌肉病

多系统RFC1疾病的自然史、表型谱与鉴别特征

Natural History, Phenotypic Spectrum, and Discriminative Features of Multisystemic RFC1 Disease.
PubMed 文献 · Neurology · 2021-01-25

该研究通过多模态RFC1重复扩增筛查和深度表型分析,在队列A(70个家系)中RFC1疾病患病率为67%,在未选择的晚发型共济失调队列B(105个家系)中为14%。70例RFC1阳性患者中69%表现为多系统受累,共济失调进展约每年1.3分SARA,为未来治疗试验提供了自然史数据。

要点

  • RFC1疾病在CANVAS和ACC中诊断率极高,分别达68%和100%。
  • 视觉补偿、感觉症状和咳嗽对RFC1阳性有强阳性预测价值(>90%)。
  • 1年试验需330例、2年试验需132例患者以检出50%的进展减缓。

核心结论

  • RFC1疾病常见且跨洲分布,CANVAS和ACC为高诊断价值表型,但属于连续多系统疾病谱的重叠群,包括与MSA-C重叠。
  • 自然史数据有助于未来RFC1治疗试验的设计。

研究设计与样本

  • 多模态RFC1重复筛查(PCR、Southern blot、全外显子/基因组测序)结合横断面和纵向深度表型分析。
  • 队列A:跨欧洲70个家系,具有≥2项CANVAS特征或共济失调伴慢性咳嗽(ACC)。
  • 队列B:土耳其105个家系,为未选择的晚发型共济失调患者。

主要发现

  • RFC1疾病患病率在队列A为67%,未选择队列B为14%,临床CANVAS为68%,ACC为100%。
  • 70例RFC1阳性患者中69%为多系统受累,包括自主神经功能障碍62%、运动迟缓28%、姿势不稳49%、慢垂直扫视17%、舞蹈症或肌张力障碍11%。
  • 共济失调进展约每年1.3分SARA(32次横断面、17次纵向评估,随访≤9年,平均3.1年),但也包括早期跌倒、MSA-C样非线性进展阶段(SARA每年2.5-5.5分)和早逝。

关键数值与推荐

  • 视觉补偿、感觉症状和咳嗽为强阳性鉴别预测因子(>90%),针对RFC1阴性患者。
  • 治疗试验需330例(1年试验)和132例(2年试验)患者总数以检测50%的进展减缓。

临床怎么用

  • 对具有CANVAS或ACC特征的患者应进行RFC1重复扩增筛查,视觉补偿、感觉症状和咳嗽有助于鉴别。
  • 认识RFC1疾病的多系统表型(包括MSA-C重叠)有助于避免误诊。
  • 自然史进展数据(约每年1.3分SARA)可用于临床咨询和试验设计。

局限性

  • 研究为观察性设计,证据级别为Class II。
  • 纵向评估样本量有限(17次纵向评估),随访时间不等。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To delineate the full phenotypic spectrum, discriminative features, piloting longitudinal progression data, and sample size calculations of replication factor complex subunit 1 (RFC1) repeat expansions, recently identified as causing cerebellar ataxia, neuropathy, vestibular areflexia syndrome (CANVAS). METHODS: Multimodal RFC1 repeat screening (PCR, Southern blot, whole-exome/genome sequencing-based approaches) combined with cross-sectional and longitudinal deep phenotyping in (1) cross-European cohort A (70 families) with ≥2 features of CANVAS or ataxia with chronic cough (ACC) and (2) Turkish cohort B (105 families) with unselected late-onset ataxia. RESULTS: Prevalence of RFC1 disease was 67% in cohort A, 14% in unselected cohort B, 68% in clinical CANVAS, and 100% in ACC. RFC1 disease was also identified in Western and Eastern Asian individuals and even by whole-exome sequencing. Visual compensation, sensory symptoms, and cough were strong positive discriminative predictors (>90%) against RFC1-negative patients. The phenotype across 70 RFC1-positive patients was mostly multisystemic (69%), including dysautonomia (62%) and bradykinesia (28%) (overlap with cerebellar-type multiple system atrophy [MSA-C]), postural instability (49%), slow vertical saccades (17%), and chorea or dystonia (11%). Ataxia progression was ≈1.3 Scale for the Assessment and Rating of Ataxia points per year (32 cross-sectional, 17 longitudinal assessments, follow-up ≤9 years [mean 3.1 years]) but also included early falls, variable nonlinear phases of MSA-C-like progression (SARA points 2.5-5.5 per year), and premature death. Treatment trials require 330 (1-year trial) and 132 (2-year trial) patients in total to detect 50% reduced progression. CONCLUSIONS: RFC1 disease is frequent and occurs across continents, with CANVAS and ACC as highly diagnostic phenotypes yet as variable, overlapping clusters along a continuous multisystemic disease spectrum, including MSA-C-overlap. Our natural history data help to inform future RFC1 treatment trials. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that RFC1 repeat expansions are associated with CANVAS and ACC.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Traschütz A, Cortese A, Reich S, et al. Natural History, Phenotypic Spectrum, and Discriminative Features of Multisystemic RFC1 Disease. Neurology. 2021. PMID: 33495376. doi:10.1212/WNL.0000000000011528

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。